Journals

</th></tr>

Arbaclofen placarbil

260px
Systematic (IUPAC) name
(3R)-3-(4-chlorophenyl)-4-[[[(1S)-2-methyl-1-[(2-methylpropanoyl)oxy]propoxy]carbonyl]amino]butanoic acid
Clinical data
Pregnancy category	N/A
Legal status	Development terminated
Identifiers
CAS Registry Number	847353-30-4
ATC code	None
PubChem	CID 11281011
ChemSpider	9456008
KEGG	D08861 7pxY
ChEMBL	CHEMBL2107312 7pxY
Chemical data
Formula	C19H26ClNO6
Molecular mass	399.86 g/mol
SMILES CC(C)[C@@H](OC(=O)C(C)C)OC(=O)NC[C@H](CC(=O)O)C1=CC=C(C=C1)Cl
InChI InChI=1S/C19H26ClNO6/c1-11(2)17(24)26-18(12(3)4)27-19(25)21-10-14(9-16(22)23)13-5-7-15(20)8-6-13/h5-8,11-12,14,18H,9-10H2,1-4H3,(H,21,25)(H,22,23)/t14-,18-/m0/s1 Key:JXTAALBWJQJLGN-KSSFIOAISA-N

Arbaclofen placarbil (ar-BAC-loe-fen pla-KAR-bil, also known as XP19986) is a prodrug of R-baclofen. Arbaclofen placarbil possesses more favorable pharmacokinetic profile than baclofen, with less fluctuations in plasma drug levels. It was being developed as a potential treatment for patients with GERD and spasticity due to multiple sclerosis; however, in May 2013 XenoPort announced the termination of development because of unsuccessful results in phase III clinical trials.

See also

• Gabapentin enacarbil
• Lesogaberan